Waverly Advisors’s Impax Laboratories, Inc. IPXL Stock Holding History

Waverly Advisors’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-83	Closed	-$2K	–	733
2014 Q3	$2K	Hold	83	–	–	﹤0.01%	738
2014 Q2	$2K	Hold	83	–	–	﹤0.01%	703
2014 Q1	$2K	Hold	83	–	–	﹤0.01%	671
2013 Q4	$2K	Buy	+83	New	+$1.85K	﹤0.01%	795

Other funds holding IPXL

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Waverly Advisors's IPXL Position: Q4 2014 in Review

Waverly Advisors sold out of Impax Laboratories, Inc. (IPXL) in Q4 2014, closing a stake of 83 shares — an estimated $2K sold.

Waverly Advisors first reported a position in IPXL in Q4 2013 and held it in 4 quarters. The position peaked at $2K in Q3 2014. 178 funds tracked by Wall St. Rank hold IPXL as of Q4 2014.

Waverly Advisors reported no remaining Impax Laboratories, Inc. position as of Q4 2014 after selling out during the quarter.
Waverly Advisors sold 83 Impax Laboratories, Inc. shares in Q4 2014, an estimated $2K.
Waverly Advisors first reported a position in Impax Laboratories, Inc. in Q4 2013 and held it in 4 quarters.
Waverly Advisors's Impax Laboratories, Inc. position peaked at $2K in Q3 2014.
178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2014.

Based on Waverly Advisors's 13F filing for Q4 2014, filed 15 Jan 2015.